<?xml version="1.0" encoding="UTF-8"?>
<p id="p0060">As ACE-2 is the binding site for SARS CoV-2, its blockade is thought to be beneficial in preventing/treating this infection. A retrospective analysis showed reduced rates of death and endotracheal intubation in patients with viral pneumonia who were continued on ACE inhibitors [
 <xref rid="bib21" ref-type="bibr">21</xref>]. Mice with coronavirus induced lung injury showed improvement when treated with an angiotensin receptor blocker, losartan [
 <xref rid="bib22" ref-type="bibr">22</xref>].As far as CVID-19 infection is concerned, the data on RAS activation or the effect of its blockadeis limited at present. Hypokalaemia and hypertension? could be a marker of RAS activation and high incidence of hypokalaemia has been reported in patients with COVID-19 infection [
 <xref rid="bib23" ref-type="bibr">23</xref>].
</p>
